All articles by David Shlaes

Antibiotics: The Perfect Storm 2024, Continuing to Evolve
( )
We Can Do Better Tackling C. diff
( )
Shionogi and Antibiotics: A Feel-good story.
( )
New Weapon Against Superbugs
( )
Let's all Shed a Tear for the Pharmaceutical Industry
( )
Paratek and Destiny. The end has finally arrived.
( )
Pull Incentive for Antibiotic R&D from Europe
( )
Entasis Scores. Now What?
( )
Antibiotics: The Perfect Storm, a Retrospective
( )
Antibiotic Biotech Execs Share Their Concerns
( )
The Fate of Another Antibiotic Biotech - Nabriva
( )
PASTEUR, Do or . . .
( )
Why Antibiotics Don't Work; Implications for Clinical Trial Design
( )
Pull Incentives for Antibiotic R&D, and Private Investment
( )
The Future of Antibiotics
( )
Entasis, Antibiotics and the Dodo
( )
Covid - Thank You to Industry - Please Do the Same for AMR
( )
Pull Incentives for AMR: Where is Biden?
( )
Europe, Antibacterials, Pull Incentives and Access
( )
Empiric Broad-Spectrum Antimicrobial Therapy is Here to Stay
( )
An American Pull Incentive. Why Not?
( )
The Pew Trust Analysis of the Antibacterial Pipeline
( )
Pull Incentives & Antimicrobial Resistance: Is Europe up to the Task?
( )
Covid Vaccines Compared to AMR
( )
Antimicrobial Resistance & Europe: What Happened?
( )
ACSH relies on donors like you. If you enjoy our work, please contribute.

Make your tax-deductible gift today!

 

 

Popular articles

ACSH Podcasts

Latest from Josh

Latest from Chuck